HNHacker News
TopNewBestAskShowJobs

criticaltinker

1,200 karma · joined July 23, 2021

submissionscomments
criticaltinker··on Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection
> 10 studies were eligible for our systematic review. The weighted average risk reduction against reinfection was 90.4% with a standard deviation of 7.7%. Protection against SARS-CoV-2 reinfection was observed for up to 10 months.

Before people dismiss these results for the typical reasons (eg it's a pre-print, etc):

1) Basically every peer-reviewed, large scale, and long-term serological study has demonstrated that immunity acquired through natural infection has been at least as effective as vaccination in preventing reinfection (eg take a look at the citations in OP). Mysteriously, it appears that none of the CDC's publications acknowledge, cite, or discuss discrepancies with any of this reputable literature.

2) The absolute risks of vaccination causing hospitalization and death are extremely low. For a vast majority of the population, the absolute risks of SARS-CoV-2 infection causing hospitalization and death are also extremely low. Folks here love to do armchair calculations of risks - or cite odds ratios from one study - to defend their view. But if you aren't stratifying by age and health then you will misrepresenting the true absolute risks for the majority of the population.

3) After infection your antibody levels will eventually drop below detectable levels, but thanks to long-lived bone marrow plasma cells and memory B cells and T cells, you are likely to retain effective protection against severe outcomes.

4) Variants of concern like delta will continue to accumulate mutations that confer a certain degree of immune escape, which will undermine protection in both vaccinated and naturally immune individuals. Comparing the effectiveness between both types of immunity (and blends of the two) is an ongoing area of research. Preliminary data from Israel suggests that natural infection may confer a more robust immune response that offers better protection when challenged by such variants (see Gazit et al., 2021, as cited in OP).

criticaltinker··on Ivermectin: * Must show pic of you and your horse *
Ivermectin used in a single-drug treatment regime has not shown significant benefits in a number of RCTs. However there is promising evidence of significant benefits when Ivermectin is used as part of a multi-drug treatment regime [1].

Since the beginning of the pandemic many front-line doctors have been combining multi-drug treatment regimes with early (in the symptomatic phase) treatment to successfully reduce hospitalization and death [2][3][4][5][6].

[1] Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial https://pubmed.ncbi.nlm.nih.gov/33983065/

[2] Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?a...

[3] Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.1...

[4] Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection https://rcm.imrpress.com/EN/article/downloadArticleFile.do?a...

[5] Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents https://www.sciencedirect.com/science/article/abs/pii/S03069...

[6] Multidrug treatment for COVID-19 https://www.jstage.jst.go.jp/article/ddt/advpub/0/advpub_202...

criticaltinker··on Why the Covid Vaccines Aren’t Dangerous
GP was referencing this study [0] when claiming "Reinfection was twice as likely among unvaccinated previously infected".

That CDC study has a relatively small sample size (N=738) and uses data from a single state during a 2-month period. The confidence interval on the "2.34" odds ratio is large (95% CI = 1.58–3.47). Most importantly, a tremendous amount of literature contradicts those findings.

Nearly every large scale and long term serological study has demonstrated that immunity acquired through previous infection is at least equally effective as vaccination in preventing reinfection. I have yet to see any CDC publication that acknowledges or cites these reputable findings. Why is that?

- A previous history of SARS-CoV-2 infection was associated with an 84% lower risk of infection, with median protective effect observed 7 months following primary infection. This time period is the minimum probable effect because seroconversions were not included. This study shows that previous infection with SARS-CoV-2 induces effective immunity to future infections in most individuals. [1] (N=25,661)

- In conclusion, documented SARS-CoV-2 reinfections were exceedingly rare, with an incidence of 0.3 infections for every 1000 persons-week, and none were severe. Seroconversion after symptomatic or asymptomatic SARS-CoV-2 infection seems to be associated with a 10-fold reduction in risk of successive viral infection contamination, lasting at least 8 months. [2] (N=1,494)

- The study results suggest that reinfections are rare events and patients who have recovered from COVID-19 have a lower risk of reinfection. Natural immunity to SARS-CoV-2 appears to confer a protective effect for at least a year, which is similar to the protection reported in recent vaccine studies. [3] (N=15,075)

- Reinfection is rare in the young and international population of Qatar. Natural infection appears to elicit strong protection against reinfection with an efficacy ~95% for at least seven months. [4] (N=192,967)

- The degree of protection (10-fold) associated with seropositivity appears to be comparable to that observed in the initial reports of the efficacy of mRNA vaccines in large clinical trials. [5] (N=3,257,478)

[0] https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm

[1] SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) https://pubmed.ncbi.nlm.nih.gov/33844963/

[2] Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study https://academic.oup.com/cid/advance-article/doi/10.1093/cid...

[3] Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy https://jamanetwork.com/journals/jamainternalmedicine/fullar...

[4] SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy https://www.sciencedirect.com/science/article/pii/S258953702...

[5] Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection https://jamanetwork.com/journals/jamainternalmedicine/fullar...

criticaltinker··on Why the Covid Vaccines Aren’t Dangerous
Yes agreed, but the benefits appear to be insignificant relative to the benefits of giving that vaccine dose to an immunologically naive or otherwise vulnerable individual.
criticaltinker··on Why the Covid Vaccines Aren’t Dangerous
Yes the lack of significant benefit from vaccinating individuals who have already acquired immunity has direct implications for public health policy. It’s not an efficient use of limited vaccine doses, especially when many vulnerable or immunologically naive people around the world have not received even one dose. These factors need to be considered because they could help reduce the total mortality from this pandemic [1].

[1] Model-informed COVID-19 vaccine prioritization strategies by age and serostatus https://science.sciencemag.org/content/sci/371/6532/916.full...

criticaltinker··on Ask HN: Can people who flagged this to death explain why?
HN can be a sensitive crowd, and it only takes a few folks to flag and completely shutdown a post.

I think the title of the post was not informative enough, and instead of linking to the GitHub repo it should’ve linked to the website which was much more informative.

It’s worth reposting to see if it gets any traction with those changes. However some topics will just be too contentious or futuristic for the crowd here. In those cases I’m always reminded of that quote from back to the future:

I guess you guys aren’t ready for that, yet. But your kids are gonna love it. - Marty McFly

criticaltinker··on Unvaccinated teacher infected half her students with Covid, CDC finds
Yes this information is in the CDC report, take a look at the seating chart with annotated infection and symptom status [1].

> 12 became infected

Using the word became is disingenuous at best (and misinformation at worst) because it implies that causation was established, but it was not. Here is the exact language from the CDC report:

> Students were seated in five rows; the attack rate in the two rows seated closest to the teacher’s desk was 80% (eight of 10) and was 28% (four of 14) in the three back rows (Fisher’s exact test; p = 0.036)

Because the students were only tested after the teacher tested positive, there is no way to determine causation from positive test results.

Even the evidence from genome sequencing could only establish correlation, but not causation.

> Eleven sequences were genetically indistinguishable from one another [...] Among the indistinguishable specimens, six were from students of the index patient, four were from students in the separate grade, and one was from a sibling of a student in the index patient’s class, suggesting that infections occurring in the two grades likely were part of the same outbreak.

[1] https://www.cdc.gov/mmwr/volumes/70/wr/mm7035e2.htm#F1_down

criticaltinker··on Unvaccinated teacher infected half her students with Covid, CDC finds
The title and narrative of this article is an egregious misreporting of the CDC report, and was obviously crafted to be divisive click bait.

Pinning this exclusively on the unvaccinated teacher is unfair and not supported by any hard facts from the CDC's investigation and findings [1].

1) Causation was not established. The delta variant was likely circulating throughout the entire school. For example, kids across multiple grade levels tested positive (these kids are not in the same classrooms). Also parents and siblings tested positive. It's extremely plausible that the teacher was not the 'index' case, even considering symptom onset dates (many infections are asymptomatic especially in children). Most importantly, since the students were only tested after the teacher tested positive, the test results cannot determine who was the true index case.

2) All 3 vaccinated adults were symptomatic, which speaks to the fact that although the vaccines are still effective at preventing severe outcomes, the delta variant has undermined vaccine efficacy at preventing infection (decreasing from 91% to 66%) [2].

> Among the five infected adults, one parent and the teacher were unvaccinated; the others were fully vaccinated. The vaccinated adults and one unvaccinated adult were symptomatic

3) This teacher should not have been at work if she had symptoms, which is partly a reflection of school policies and the lacking benefits of many elementary school teachers in general (eg limited paid time off).

[1] https://www.cdc.gov/mmwr/volumes/70/wr/mm7035e2.htm

[2] https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e4.htm

criticaltinker··on Unvaccinated teacher infected half her students with Covid, CDC finds
> The key problem with anti-vaxxers

Before you turn this into a bitter vax versus anti-vax debate through unjustified insinuations about the teacher, you need to acknowledge two important nuances from the CDC report [1]:

1) Causation was not established. The delta variant was likely circulating throughout the entire school. For example, kids across multiple grade levels tested positive (these kids are not in the same classrooms). Also parents and siblings tested positive. It's very plausible that the teacher was not the 'index' case, even considering symptom onset dates (many infections are asymptomatic especially in children).

2) All 3 vaccinated adults were symptomatic, which speaks to the fact that although the vaccines are still effective at preventing severe outcomes, the delta variant has undermined the efficacy at preventing infection (from 91% to 66%) [2].

> Among the five infected adults, one parent and the teacher were unvaccinated; the others were fully vaccinated. The vaccinated adults and one unvaccinated adult were symptomatic

[1] https://www.cdc.gov/mmwr/volumes/70/wr/mm7035e2.htm

[2] https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e4.htm

criticaltinker··on Israeli Study: Natural Immunity Is 13x Stronger Than Pfizer Covid Shots
This is not a valid comparison because you're using the case fatality rate (1.8%), and case means symptomatic illness (a majority of infections are not symptomatic). A fair comparison would use the infection fatality rate (IFR), which is the risk of death after being infected.

Recent meta analyses estimate a global average IFR of ~0.15% [1], which is extremely biased by age. All age stratified IFRs show risk that decreases by orders of magnitude with age. We're talking IFRs below 0.003% for healthy young adults and children [2][3].

I'm not advocating against vaccination, just illustrating that the risk-reward profile is different for everyone based on their age and health. If you want to derive useful probabilistic risk estimates, there are many complex factors to consider.

[1] Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications https://link.springer.com/article/10.1007/s10654-020-00698-1

[2] Infection fatality rate of COVID-19 inferred from seroprevalence data https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947934/

[3] COVID-19 antibody seroprevalence in Santa Clara County, California https://academic.oup.com/ije/article/50/2/410/6146069

criticaltinker··on Israeli Study: Natural Immunity Is 13x Stronger Than Pfizer Covid Shots
Yes although the delta variant has undermined the efficacy of vaccines at preventing infection (from 91% to 66% [1]), it is still fairly effective at preventing severe outcomes such as hospitalization and death.

> but a poor basis on which to shift policy from vaccination to infecting the entire population and blessing the survivors

This is not at all what the paper is suggesting, and people should not be interpreting it as such. The fact is that a vast majority of people infected by SARS-CoV-2 will survive without any severe outcomes. In fact a significant proportion (at least 33% and up to 65% [2][3], perhaps even more [4][5]) will be completely asymptomatic.

This has implications for vaccine strategy because supply of doses is limited - these findings imply that individuals who are immunologically naive or vulnerable due to age and comorbidities should be prioritized for vaccination, rather than people who have already acquired robust and durable immunity from natural infection [6].

[1] https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e4.htm

[2] The Proportion of SARS-CoV-2 Infections That Are Asymptomatic https://www.acpjournals.org/doi/full/10.7326/M20-6976

[3] Estimating the asymptomatic proportion of SARS-CoV-2 infection in the general population: Analysis of nationwide serosurvey data in the Netherlands https://link.springer.com/article/10.1007/s10654-021-00768-y

[4] Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters https://www.sciencedirect.com/science/article/pii/S253104372...

[5] Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States https://stm.sciencemag.org/content/13/601/eabh3826

[6] Model-informed COVID-19 vaccine prioritization strategies by age and serostatus https://science.sciencemag.org/content/sci/371/6532/916.full...

criticaltinker··on Israeli Study: Natural Immunity Is 13x Stronger Than Pfizer Covid Shots
This pre-print study has been discussed a few times on HN recently [1][2].

Many people are commenting that this paper is flawed by survivorship bias. While it would be useful to know the "cumulative" risk of SARS-CoV-2 infection, the fact is that a vast majority of people survive initial infection. So it is also useful to know the pure risk associated with reinfection - to inform public health policy and vaccine research.

That is why the purpose of this research is to evaluate the risk of reinfection by directly comparing the effectiveness of natural immunity and vaccine-induced immunity in the context of the delta variant, which has mutations that confer partial immune escape. This research is significant because it is one of the first and largest studies to do so.

[1] https://news.ycombinator.com/item?id=28327482 (350 comments)

[2] https://news.ycombinator.com/item?id=28317866 (226 comments)

criticaltinker··on 90% of SARS-CoV-2 infections may have been unreported in CA and FL by Mar 2020
> The first 30 days since the outbreak of the COVID-19 epidemic in the two states (i.e., for the month of March as per the timeline of this study) experienced extremely high level of underreporting, with the estimated average percentages of underreporting being 96.6% for California, and 93.9% for Florida.

> Similar results have been reported by Lau et al. [8]. Based on the reported data till 17 March 2020, they estimated the true number of infecteds to be 53.8 times higher than the reported number of cases in the United States- i.e., 98.1% of the total cases remained unreported.

> Similar situation was also reported by Wu et al. [7], and as per their findings the ratios of estimated cases to confirmed infections in California and Florida till 18 April 2020 were around 17.5 (94.3% underreported cases) and 10 (90% unreported cases), respectively.

criticaltinker··on Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated individuals
The window for SARS-CoV-2 antibody tests would be at least 8 months to a year for many individuals.

More expensive tests can detect immunity based on T cells for example, which would provide an even longer window.

And of course really expensive and invasive bone marrow aspirate tests could provide a window approaching a lifetime - but the tradeoffs involved there would likely be unfavorable for practical “proof”. Who knows what technology we’ll come up with in the future though.

criticaltinker··on Unclassified Summary of Assessment on Covid-19 Origins
> After examining all available intelligence reporting and other information, though, the IC remains divided on the most likely origin of COVID-19. All agencies assess that two hypotheses are plausible: natural exposure to an infected animal and a laboratory-associated incident.

> China’s cooperation most likely would be needed to reach a conclusive assessment of the origins of COVID-19. Beijing, however, continues to hinder the global investigation, resist sharing information and blame other countries, including the United States.

For those following the topic, there doesn’t seem to be any new information here. We still have no conclusive evidence and are blocked by political impasse.

criticaltinker··on Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated individuals
> Ideally, everyone would be tested for antibodies before receiving a vaccine

I agree that would help make optimal decisions with regards to distributing a limited supply of vaccine doses.

However it's worth noting that even when antibodies drop below levels detectable by standard tests, individuals are likely to retain robust immune responses that provide sufficient protection from severe outcomes [1][2].

[1] SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans https://www.nature.com/articles/s41586-021-03647-4.pdf

[2] Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies https://www.journalofinfection.com/article/S0163-4453(21)002...

criticaltinker··on Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated individuals
The biggest flaw with this study is that it does not account for prior natural infection. It has been thoroughly demonstrated that individuals who acquire immunity through natural infection have a robust and durable immune response [1][2][3]. Recent vaccination on top of this immunity is likely to further prime and improve immune responses to subsequent infection [4][5].

Not accounting for this fact is a significant confounding factor in the study, and I'm disappointed the authors made no distinction between unvaccinated and immunologically naive. This is a distinction that every sensible scientific discussion needs to acknowledge.

EDIT: please leave a comment down voters, I’m starting to think there’s some sort of targeted campaign against this type of information

> Vaccine breakthrough infections exhibited similar proliferation dynamics as infections in unvaccinated individuals (mean peak Ct: 20.5, 95% credible interval [19.0, 21.0] vs. 20.7 [19.8, 20.2], and mean proliferation time 3.2 days[2.5, 4.0] vs. 3.5 days [3.0, 4.0]); however, vaccinated individuals exhibited faster clearance (mean clearance time: 5.5 days [4.6, 6.6] vs. 7.5 days [6.8, 8.2]).

> If the Ct values in vaccinated and unvaccinated infected individuals reflect the same amounts of infectious virus, then this implies that individuals with breakthrough infections may be as infectious as unvaccinated individuals in the early stage of the infection, but remain infectious for a shorter time, reducing the total degree of onward transmission. These findings are in keeping with the hypothesis that vaccination protects against the severe manifestations of disease but offers less protection against infection in the upper airway. Precautions are therefore necessary to prevent onward transmission even from vaccinated individuals.

[1] Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells https://www.cell.com/cell-reports-medicine/fulltext/S2666-37...

[2] SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) https://pubmed.ncbi.nlm.nih.gov/33844963/

[3] Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection https://jamanetwork.com/journals/jamainternalmedicine/fullar...

[4] Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection https://www.nature.com/articles/s41586-021-03696-9

[5] Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine https://www.nature.com/articles/s41591-021-01316-7

criticaltinker··on Having SARS-CoV-2 once confers much greater immunity than a vaccine
So far a multitude of randomized clinical trials (RCTs) have tried but not found significant benefits from using Ivermectin to treat COVID-19 in a single-drug treatment regime.

However it's worth noting that certain multi-drug treatment regimes are looking quite promising [1][2].

Furthermore, early multi-drug treatment (before severe symptoms) using existing widely available medicines has been proven effective at reducing hospitalization and death [3][4][5][6][7]. Many front-line doctors have been using such techniques since the beginning of the pandemic, because they had to - as there were no vaccines yet and no RCTs to guide them so naturally the only option was using and combining existing medicines with established safety and efficacy profiles, the same strategy used for other difficult to treat diseases and cancers.

[1] Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial https://pubmed.ncbi.nlm.nih.gov/33983065/

[2] Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 https://pubmed.ncbi.nlm.nih.gov/33306283/

[3] Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.1...

[4] Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection https://rcm.imrpress.com/EN/article/downloadArticleFile.do?a...

[5] Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents https://www.sciencedirect.com/science/article/abs/pii/S03069...

[6] Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?a...

[7] Multidrug treatment for COVID-19 https://www.jstage.jst.go.jp/article/ddt/advpub/0/advpub_202...

criticaltinker··on Having SARS-CoV-2 once confers much greater immunity than a vaccine
You raise a good point that it would be useful to report the "cumulative" risk for people previously infected.

However the goal of this research is specifically evaluating risk of reinfection, not the cumulative risk of SARS-COV-2 infection. The fact is that a vast majority of people survive initial SARS-COV-2 infection, so the pure risks associated with reinfection are also equally useful to know.

The decision to focus on delta infections does impact the OR estimates for vaccine effectiveness as you mention. But again this was one of the primary research goals of the paper - to evaluate the risk of reinfection by comparing natural immunity to vaccine-induced immunity in the context of a variant with mutations conferring immune escape.

> the variants that provided that natural immunity are not "dominant" anymore

This was controlled for in the study by censoring data based on the date of previous infection.

> The trade-off is that natural immunity has the "side effect" of actually having to fight off and survive the illness?

Yes, and people need to stop interpreting the title and cited paper as a manifesto against vaccination. Rather, the study provides valuable data on the efficacy of natural and vaccine induced immunity in the context of evolving variants, which will be useful in guiding public health policy and also formulating next generation vaccines that improve upon the current formulations.

criticaltinker··on Reddit CEO Rejects Call to Take Down Covid-19 Disinformation
I don't care whose side you're on - compared to ten years ago, the front page of Reddit has absolutely become infiltrated with deliberately crafted narratives clearly intended to push certain agendas.

This call to action by "volunteer moderators" is ironic in that sense, because there are likely even bigger more impactful systematic campaigns of disinformation going on - see this recent discussion from yesterday for some great insight into why and how these campaigns may be orchestrated [1].

[1] Almost all of the top subreddits are moderated by the same people (291 comments) https://news.ycombinator.com/item?id=28312261

criticaltinker··on Having SARS-CoV-2 once confers much greater immunity than a vaccine
> If you want that first time to be with prior immunity get vaccinated as that is the only known way to get immunity before your first infection.

Not disagreeing with your general point, but this statement is not accurate. For example, cross-reactive antibodies from other common cold coronaviruses can provide immune protection [1], which may partially explain why a large fraction of people are completely asymptomatic after initial SARS-COV-2 infection.

> COVID-19 patients elicit strong responses to the nucleocapsid (N) protein of SARS-CoV-2 but binding antibodies are also detected in prepandemic individuals, indicating potential crossreactivity with common cold human coronaviruses (HCoV) [1]

> In our study, we speculate that preexisting OC43 HCoV IgGs to N protein could be protective and, as a result, incoming SARS-CoV-2 infections would be more controlled and thus fewer antibodies induced against them.

> In conclusion, N protein is a primary target of SARS-CoV-2-specific and HCoV crossreactive antibodies, both of which may affect the acquisition of immunity to COVID-19. [1]

[1] Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879156/

criticaltinker··on Having SARS-CoV-2 once confers much greater immunity than a vaccine
Yes thank you. GPs comment is completely inaccurate, and the referenced study does not make any claims about natural infection, only about patients hospitalized with severe illness.

Multiple recent large scale studies have estimated an asymptomatic proportion lower bound of at least ~33% [1], and an upper bound of 65% (and even higher for young adults) [2]. This implies a significant proportion of people infected by SARS-COV-2 will not experience any noticeable symptoms.

Furthermore, there is strong evidence that infections and cases are massively under-reported (by 10x to 100x) [3][4], so it's exceedingly likely that such estimates are underestimates of the true asymptomatic rate.

[1] The Proportion of SARS-CoV-2 Infections That Are Asymptomatic https://www.acpjournals.org/doi/full/10.7326/M20-6976

[2] Estimating the asymptomatic proportion of SARS-CoV-2 infection in the general population: Analysis of nationwide serosurvey data in the Netherlands https://link.springer.com/article/10.1007/s10654-021-00768-y

[3] Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters https://www.sciencedirect.com/science/article/pii/S253104372...

[4] Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States https://stm.sciencemag.org/content/13/601/eabh3826

criticaltinker··on Having SARS-CoV-2 once confers much greater immunity than a vaccine
Individuals who were naturally infected and then vaccinated, or vice-versa, should be well protected. It is unclear if a combination of the two provides better immunity especially when challenged by variants of concern. However, preliminary in vitro evidence (cited in OP) suggests that yes, a combination of the two may confer better short-term protection than either one alone [1].

> The data suggest that immunity in convalescent individuals will be very long lasting and that convalescent individuals who receive available mRNA vaccines will produce antibodies and memory B cells that should be protective against circulating SARS-CoV-2 variants. [1]

[1] Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection https://www.nature.com/articles/s41586-021-03696-9

criticaltinker··on Having SARS-CoV-2 once confers much greater immunity than a vaccine
It's important to be aware of the tremendous amount of evidence from a wide body of peer-reviewed literature which supports the fact that immunity acquired through natural infection provides protection against reinfection that is at least equally effective as vaccination. This fact has been repeatedly demonstrated in multiple large scale and long term serological studies [1][2][3][4][5].

It's still an open question whether natural infection confers better protection than vaccine-induced immunity, or if some combination of the two is even better. That's why the primary pre-print cited in OP is so important [6]. It is one of the first and largest scale studies to evaluate the risk of reinfection - in the context of the delta variant which is currently dominant in many countries around the world - by directly comparing naturally acquired immunity to vaccine-induced immunity.

The other cited papers in OP give some reasoning why natural infection might confer more robust protection, particularly when challenged by variants of concern [7][8][9]. The gist is that the immune response acquired through natural infection evolves in such a way that broader and more diverse antibodies can be developed. Another major difference is that natural infection induces antibodies against the nucleocapsid (N) protein, whereas vaccination with the current mRNA based spike protein focused formulations do not [10][11].

All of these findings have major implications for public health policy. In particular, optimal vaccination strategy should likely be targeted towards immunologically naive individuals, or individuals more vulnerable due to age and poor health [12].

- A previous history of SARS-CoV-2 infection was associated with an 84% lower risk of infection, with median protective effect observed 7 months following primary infection. This time period is the minimum probable effect because seroconversions were not included. This study shows that previous infection with SARS-CoV-2 induces effective immunity to future infections in most individuals. [1] (N=25,661)

- Reinfection is rare in the young and international population of Qatar. Natural infection appears to elicit strong protection against reinfection with an efficacy ~95% for at least seven months. [4] (N=192,967)

- The degree of protection (10-fold) associated with seropositivity appears to be comparable to that observed in the initial reports of the efficacy of mRNA vaccines in large clinical trials. [5] (N=3,257,478)

> those vaccinated are still at a 5.96-fold increased risk for breakthrough infection and at a 7.13-fold increased risk for symptomatic disease compared to those previously infected. [6]

> SARS-CoV-2-naïve vaccinees were also at a greater risk for COVID-19-related-hospitalization compared to those who were previously infected. [6]

[1] SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) https://pubmed.ncbi.nlm.nih.gov/33844963/

[2] Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study https://academic.oup.com/cid/advance-article/doi/10.1093/cid...

[3] Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy https://jamanetwork.com/journals/jamainternalmedicine/fullar...

[4] SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy https://www.sciencedirect.com/science/article/pii/S258953702...

[5] Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection https://jamanetwork.com/journals/jamainternalmedicine/fullar...

[6] Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v...

[7] Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection https://www.nature.com/articles/s41586-021-03696-9

[8] Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations https://pubmed.ncbi.nlm.nih.gov/34331873/

[9] High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1

[10] Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2 https://www.cell.com/cell-reports/pdf/S2211-1247(21)01108-6....

[11] Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879156/

[12] Model-informed COVID-19 vaccine prioritization strategies by age and serostatus https://science.sciencemag.org/content/sci/371/6532/916.full...

criticaltinker··on Immunity Generated from Covid-19 Vaccines Differs from an Infection
> COVID-19, on the other hand, has an overall 1.66% chance of killing someone (38,043,754 cases, 629,644 deaths)

What you calculated is the case fatality rate (CFR), but the infection fatality rate (IFR) is a better representation of risk from SARS-COV-2 infection.

The global average IFR is recently estimated to be ~0.15% [1], which is extremely skewed by age.

All estimates of age stratified IFR show a gradient that decreases by orders of magnitude with age - we're talking IFRs below 0.003% for healthy young adults and children [2][3].

Furthermore, there is substantial evidence that the CFRs & IFRs are significant overestimates [5]. This completely changes the risk-reward tradeoff for many people.

I am not advocating against vaccination (it is a powerful tool that saves lives) - just spreading knowledge and illustrating the fact that everyone has a different risk-reward profile based on their age and health, and should make personal health decisions accordingly.

[1] Reconciling estimates of global spread and infection fatality rates of COVID- 19: An overview of systematic evaluations https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/eci.13...

[2] Infection fatality rate of COVID-19 inferred from seroprevalence data https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947934/

[3] COVID-19 antibody seroprevalence in Santa Clara County, California https://academic.oup.com/ije/article/50/2/410/6146069

[4] Model-informed COVID-19 vaccine prioritization strategies by age and serostatus https://science.sciencemag.org/content/sci/371/6532/916.full...

[5] Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters https://www.sciencedirect.com/science/article/pii/S253104372...

criticaltinker··on Immunity Generated from Covid-19 Vaccines Differs from an Infection
> unequivocally states that vaccine-induced immunity is more robust than that from infection.

It absolutely does not make such a strong claim - a more accurate takeaway is that vaccination using the current mRNA based formulations induces an immune response highly targeted toward the S protein RBD. This has not been conclusively proven to provide better or worse protection than immunity acquired through natural infection.

> At first glance, the RBD targeting of the vaccine sera neutralization might seem likely to increase susceptibility to viral mutations, but the rest of our results SUGGEST that this MAY not be the case.

> We found that the specificity of the mRNA-1273 vaccine-induced RBD-binding antibody response often narrows over time. In contrast, the infection-elicited RBD-binding antibody response often broadens over time

> The vaccinated individuals in our study were relatively young (18–55 years) and healthy, whereas the convalescent individuals were older (23–76 years, median 56) with a range of comorbidities (13).

> Additionally, we did not examine effects of mutations or deletions to the N-terminal domain of the spike protein, which can also affect neutralization by vaccine sera (7).

> Our experiments assayed binding of antibodies to isolated RBD expressed by yeast, and so cannot capture mutational effects on trimer conformation or antibodies with quaternary epitopes

> Evidence from multiple experimental studies showing that single RBD point mutations can lead to resistance to neutralizing convalescent plasma from multiple donors suggests that specific single mutants may be able to evade spike-targeting vaccinal immunity in many individuals and rapidly lead to spread of vaccine-resistant SARS-CoV-2. [1]

[1] Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein https://pubmed.ncbi.nlm.nih.gov/33909660/

criticaltinker··on Immunity Generated from Covid-19 Vaccines Differs from an Infection
Solid layman reasoning, just wanted to clear up one slight misconception:

> mRNA vaccines used the spike protein because we believe that to be the most conserved proteins

The spike protein was chosen mostly because it was well known to serve a primary role in the process of infection and subsequent immune response. Ongoing vaccine research is exploring the use of additional proteins, because they have been demonstrated to be a major factor in viral replication and protective immunity. For example, nucleocapsid (N) protein antibodies are induced by natural infection, but not by vaccination using the current solely spike protein focused mRNA vaccine formulations. N protein antibodies likely have a synergistic effect with S protein antibodies, and thus vaccine formulations incorporating both elements may result in more robust protection, especially against variants.

See my other comment on this thread for supporting excerpts and citations from the literature.

[1] https://news.ycombinator.com/item?id=28320340

criticaltinker··on Immunity Generated from Covid-19 Vaccines Differs from an Infection
> It does not support any specific mechanistic explanation.

You're right that the recent pre-print cited by GP - regarding the data out of Israel - does not prove or disprove any specific mechanistic explanation.

However, interpreting GPs comment charitably, that study does support the notion that immunity acquired through natural infection may be more robust to mutations and variants - the mechanisms of which have been articulated in a variety of other literature. See my sibling comment [1] for supporting citations and excerpts.

[1] https://news.ycombinator.com/item?id=28320340

criticaltinker··on Immunity Generated from Covid-19 Vaccines Differs from an Infection
> Why is the article saying the opposite?

The cited study in OP may have a slightly pro-vaccine bias, potentially because two authors have "the potential to receive a share of IP revenue" on a relevant patent, and because one author consults for Moderna. Regardless, the study presents scientifically accurate findings, but in a few places it tries to stretch those into questionable conclusions. For example, the authors write:

> At first glance, the RBD targeting of the vaccine sera neutralization might seem likely to increase susceptibility to viral mutations, but the rest of our results suggest that this MAY not be the case. [4]

So keep that tilt in mind when reading it.

> one might expect targeting a wider variety of places on on the COVID spike protein to result in better immunity against variants

Yes this is good intuition, here are excerpts from other literature illustrating why targeting a wide variety of SARS-COV-2 proteins can provide better immunity. In fact, this reasoning is why ongoing vaccine research is investigating formulations beyond the current solely spike protein focused vaccines. Notably, one shortcoming of the current mRNA vaccine formulations is that they do not induce nucleocapsid (N) protein antibodies - whereas natural infection does.

> The nucleocapsid protein of SARS-CoV-2 has been suggested to be an important target for T cell responses. [1]

> Firstly, this protein contains conserved cross-reactive T cell epitopes that are present among different coronaviruses, suggesting that it could be an ideal target for universal coronavirus vaccines. [1]

> Secondly, the nucleocapsid protein is among the most abundant structural proteins in the coronavirus lifecycle, which may facilitate early antigen presentation and recognition by T cells. [1]

> Previous knowledge on other related coronaviruses and the prompt sequencing of the SARS-CoV-2 genome early in the pandemic allowed to identify the spike (S) and the nucleocapsid (N) structural proteins as major targets of antibodies. [2]

> The surface glycoprotein S, which contains the receptor-binding domain (RBD), has a better known function in immunity and is the leading antigen candidate for vaccine development. N is smaller than S, lacks a glycosylation site, and is extensively used in leading serodiagnostics kits due to its abundant expression during infection and early antibody response but its immunological relevance is less established. [2]

> N forms ribonucleoprotein complexes during the virion assembly process by binding to the viral RNA genome and packing it into long helical structures. Its main function is to regulate viral RNA transcription during replication, promoting the synthesis of its own proteins while interfering with the metabolism, protein translation, and proliferation of the infected host cell. During the process of infection, N dissociates itself from the genome and is exposed to the host immune system, and its high immunogenicity has also prompted its exploration as vaccine target. [2]

> Interestingly, significant protein similarity between SARS-CoV-1, SARS-CoV-2, and other HCoV has been reported for N, including a highly conserved motif in the N-terminal (NT) half of the protein (FYYLGTGP) and relevant immunodominant epitope regions. [2]

> Evidence from multiple experimental studies showing that single RBD point mutations can lead to resistance to neutralizing convalescent plasma from multiple donors suggests that specific single mutants may be able to evade spike-targeting vaccinal immunity in many individuals and rapidly lead to spread of vaccine-resistant SARS-CoV-2. [3]

[1] Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2 https://www.cell.com/cell-reports/pdf/S2211-1247(21)01108-6....

[2] Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879156/

[3] Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein https://pubmed.ncbi.nlm.nih.gov/33909660/

[4] Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection https://pubmed.ncbi.nlm.nih.gov/34103407/

criticaltinker··on Mask mandate and use efficacy for Covid-19 containment in US States
> There's overwhelming evidence that mask use is effective in retarding the spread of COVID-19

It's probably not fair to phrase it as overwhelming evidence. Yes there is evidence that masks can reduce transmission, and the citations you provided included a fair amount of research supporting this idea (thanks for those references). And just thinking about it logically, it seems obvious masks would have such an effect.

However the evidence presented in OP - and the previous studies it cited - provide counter-evidence suggesting that mask usage and mandates may not have a significant beneficial impact on the overall course of a pandemic.

There are a variety of possible reasons for this, which you began to speculate on. Poor compliance, people not wearing their masks correctly, porous cloth masks, poorly ventilated indoor environments contributing to high viral load environments even with 100% mask compliance - the number of places where things can go wrong are tremendous and it begs the question of if the tradeoffs of mask mandates are worth it, or if our resources would be better spent on other viral elimination strategies.

← PreviousPage 5 of 15Next →